Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.57 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.57 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | TYR | P14679 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL321329 | 1.00 | NFE2L2 (0.57) | NFE2L2HCAR2KEAP1ALDH1A1MAPT | |
| SCHEMBL4414935 | 0.81 | HCAR2 (0.52) | NFE2L2HCAR2KEAP1ALDH1A1MAPT | |
| SCHEMBL4414937 | 0.81 | HCAR2 (0.52) | NFE2L2HCAR2KEAP1ALDH1A1MAPT | |
| SCHEMBL4460434 | 0.81 | HCAR2 (0.46) | NFE2L2HCAR2KEAP1ALDH1A1MAPT | |
| SCHEMBL4460429 | 0.81 | HCAR2 (0.46) | NFE2L2HCAR2KEAP1ALDH1A1MAPT | |
| SCHEMBL776038 | 0.79 | — | — | |
| SCHEMBL21847990 | 0.79 | — | — | |
| SCHEMBL28254645 | 0.78 | HCAR2 (0.48) | NFE2L2HCAR2KEAP1ALDH1A1MAPT | |
| SCHEMBL1881404 | 0.77 | NFE2L2 (0.60) | NFE2L2HCAR2KEAP1ALDH1A1MAPT | |
| SCHEMBL3022767 | 0.77 | NFE2L2 (0.60) | NFE2L2HCAR2KEAP1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030194378-A1 | Novel aerosol formulation containing a polar fluorinated molecule | ASTRAZENECA AB (SE) | 2003-10-16 | — | — | US | claimed |
| EP-1303258-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | AstraZeneca AB (SE) | 2003-04-23 | — | — | EP | claimed |
| WO-2002003958-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | ASTRAZENECA AB (SE) | 2002-01-17 | — | — | WO | claimed |
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | CIT THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4262788-B1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20240360148-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | CIT THERAPEUTICS LLC | 2024-10-31 | — | — | US | disclosed |
| EP-4373825-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | Suvalent Therapeutics, Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| EP-4262788-A1 | UREA OREXIN RECEPTOR AGONISTS | Merck Sharp & Dohme LLC (US) | 2023-10-25 | — | — | EP | disclosed |
| WO-2023004376-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | Suvalent Therapeutics, Inc. (US) | 2023-01-26 | — | — | WO | disclosed |
| CN-112645890-B | Synthesis method of 2-pyrazine carboxylic ester compound | 江苏广域化学有限公司 | 2022-08-12 | — | — | CN | disclosed |
| WO-2022132696-A1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-06-23 | — | — | WO | disclosed |
| EP-1338336-A1 | CATALYSTS COMPRISING N-SUBSTITUTED CYCLIC IMIDES AND PROCESSES FOR PREPARING ORGANIC COMPOUNDS WITH THE CATALYSTS | Daicel Chemical Industries, Ltd. (JP) | 2003-08-27 | — | — | EP | disclosed |
| EP-1303258-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | AstraZeneca AB (SE) | 2003-04-23 | — | — | EP | disclosed |
| US-20030013603-A1 | Catalyst comprising n-substituted cylic imides and processes for preparing organic compounds with the catalyst | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2003-01-16 | — | — | US | disclosed |
| US-20020128149-A1 | Catalyst comprising a cyclic imide compound and process for producing organic compounds using the catalyst | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2002-09-12 | — | — | US | disclosed |
| EP-1238704-A2 | Catalyst comprising a cyclic imide compound and process for producing organic compounds using the catalyst | Daicel Chemical Industries, Ltd. (JP) | 2002-09-11 | — | — | EP | disclosed |
| US-6403521-B1 | FOR OXIDATION, NITRATION, CARBOXYLATION, SULFONATION; NO EXHAUST GAS TREATMENT; 6-TRIFLUOROMETHYL-L-HYDROXY BENZOTRIAZOLE; 3-HYDROXY-4-OXO-1,2,3-BENZOTRIAZINE TO OXIDIZE FLUORENE TO FLUORENONE; ADAMANTANE TO ADAMANTANOL | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2002-06-11 | — | — | US | disclosed |
| WO-2002003958-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | ASTRAZENECA AB (SE) | 2002-01-17 | — | — | WO | disclosed |
| EP-1085015-A2 | Catalyst comprising a nitrogen-containing heterocylic compound | Daicel Chemical Industries, Ltd. (JP) | 2001-03-21 | — | — | EP | disclosed |
| EP-1055654-A1 | PROCESS FOR THE PREPARATION OF ORGANIC COMPOUNDS WITH IMIDE CATALYSTS | Daicel Chemical Industries, Ltd. (JP) | 2000-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360148-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | SUMO1, SUMO3, SUMO2 | NFE2L2 1393/4885HCAR2 4427/4885KEAP1 329/4885 |
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | SUMO1, SUMO3, PSMB6 | NFE2L2 2373/4885HCAR2 3471/4885KEAP1 472/4885 |
| US-20020128149-A1 | Catalyst comprising a cyclic imide compound and process for producing organic compounds using the catalyst | NOX4, POR, NOX1 | NFE2L2 58/4885HCAR2 3074/4885KEAP1 497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.